REgulatory T Cell Therapy to Achieve Immunosuppression REduction
NCT06552169
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will be randomized to one of 2 study arms: Arm 1 subjects will receive standard of care immunosuppression Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Kidney Transplantation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Singulera Therapeutics Inc.
- Last updated on ClinicalTrials.gov
- April 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic in Arizona · Phoenix, AZ
Illinois · 1
- Northwestern Memorial Hospital · Chicago, IL
Minnesota · 1
- Mayo Clinic in Minnesota · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.